Journal of Thoracic Oncology最新文献

{"title":"PP01.06 Aurora Kinase A Inhibition Potentiates KRASG12C Inhibition and Overcomes Resistance to Sotorasib in Lung Cancer","authors":"Jong Woo Lee, Jackie Shi, Julian Barrantes, Sundong Kim, Sebastian Cruz-Gomez, Cindy Yang, Barbara Burtness","doi":"10.1016/j.jtho.2025.03.014","DOIUrl":"10.1016/j.jtho.2025.03.014","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S5"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA05.01 Deep Mutational Scanning Reveals Novel EGFR Mutations Conferring Resistance to Osimertinib and BLU-945","authors":"Dylan Yueyang Wang , Michela Ranieri , Fiona Sherman , Jiehui Deng , Kwok-Kin Wong , Elaine Shum , John T. Poirier","doi":"10.1016/j.jtho.2025.03.007","DOIUrl":"10.1016/j.jtho.2025.03.007","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S2"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.14 Paired Sample Analyses of NSCLC After SCLC Transformation","authors":"Brinda Gupta , Kieran Sweeney , Andrew Elliott , Jennifer Marks , Ari Vanderwalde , Sonam Puri , Misty D. Shields , Jorge J. Nieva , Heloisa P. Soares , Patrick C. Ma , Balazs Halmos , Stephen V. Liu","doi":"10.1016/j.jtho.2025.03.021","DOIUrl":"10.1016/j.jtho.2025.03.021","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S8"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.04 Targeting the Minimal Residual Disease to Increase the Targeted Therapy Depth of Response in EGFR-Driven Lung Cancer","authors":"David Bracquemond , Maicol Mancini , Antonio Maraver","doi":"10.1016/j.jtho.2025.03.012","DOIUrl":"10.1016/j.jtho.2025.03.012","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S4"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report","authors":"Batel Blechter PhD ,&nbsp;Chao Agnes Hsiung PhD ,&nbsp;Xiaoyu Wang MS ,&nbsp;Haoyu Zhang PhD ,&nbsp;Wei Jie Seow PhD ,&nbsp;Jianxin Shi PhD ,&nbsp;Nilanjan Chatterjee PhD ,&nbsp;Hee Nam Kim MD, PhD ,&nbsp;Maria Pik Wong MD ,&nbsp;Yun-Chul Hong MD, PhD ,&nbsp;Jason Y.Y. Wong PhD ,&nbsp;Juncheng Dai PhD ,&nbsp;H. Dean Hosgood PhD ,&nbsp;Zhaoming Wang PhD ,&nbsp;I-Shou Chang PhD ,&nbsp;Jiyeon Choi PhD ,&nbsp;Jiucun Wang PhD ,&nbsp;Minsun Song PhD ,&nbsp;Wei Hu PhD ,&nbsp;Wei Zheng MD, PhD ,&nbsp;Qing Lan MD, PhD","doi":"10.1016/j.jtho.2024.11.019","DOIUrl":"10.1016/j.jtho.2024.11.019","url":null,"abstract":"<div><div>We assessed the association between a genome-wide polygenic risk score (PRS) developed for lung adenocarcinoma (LUAD) risk and mutation on the <em>EGFR</em> gene in 998 East Asian never-smoking female LUAD cases (518 <em>EGFR</em>-positive; 480 <em>EGFR</em>-negative) and 4544 never-smoking controls using case-case and multinomial regression analyses. We found that the PRS was more strongly associated with <em>EGFR</em>-positive LUAD compared with <em>EGFR</em>-negative LUAD, where the association between the fourth quartile of the PRS and <em>EGFR</em>-positive LUAD (odds ratio = 8.63, 95% confidence interval: 5.67–13.14) was significantly higher than the association between the fourth quartile of the PRS with <em>EGFR</em>-negative LUAD (odds ratio = 3.50, 95% confidence interval: 2.44–5.00) (p-heterogeneity = 3.66 × 10⁻³). Our findings suggest that germline genetic susceptibility may be differentially associated with LUAD in never-smoking female East Asian patients depending on the cancer's mutation status, which may have important public health and clinical implications.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 521-530"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","authors":"Kazuhiko Nakagawa MD, PhD ,&nbsp;Edward B. Garon MD, MS ,&nbsp;Takashi Seto MD, PhD ,&nbsp;Makoto Nishio MD, PhD ,&nbsp;Santiago Ponce Aix MD ,&nbsp;Luis Paz-Ares MD, PhD ,&nbsp;Chao-Hua Chiu MD ,&nbsp;Keunchil Park MD, PhD ,&nbsp;Silvia Novello MD, PhD ,&nbsp;Ernest Nadal MD, PhD ,&nbsp;Kazumi Nishino MD, PhD ,&nbsp;Kiyotaka Yoh MD ,&nbsp;Jin-Yuan Shih MD, PhD ,&nbsp;Jeannie Y.K. Chik M.B.B.S. ,&nbsp;Denis Moro-Sibilot MD, PhD ,&nbsp;Tarun Puri MD ,&nbsp;Sunoj Chacko Varughese MSc ,&nbsp;Bente Frimodt-Moller MSc ,&nbsp;Carla Visseren-Grul MD ,&nbsp;Martin Reck MD, PhD","doi":"10.1016/j.jtho.2024.11.032","DOIUrl":"10.1016/j.jtho.2024.11.032","url":null,"abstract":"<div><h3>Introduction</h3><div>RELAY, a global double-blind, placebo-controlled phase 3 study (NCT02411448) found statistically significant improvement in progression-free survival (primary end point) for ramucirumab (RAM) plus erlotinib (ERL) (RAM + ERL) in patients with untreated <em>EGFR</em>-mutated metastatic NSCLC (hazard ratio [HR] = 0.59, 95% confidence interval [CI]: 0.46–0.76, <em>p</em> &lt; 0.0001; median progression-free survival: 19.4 versus 12.4 mo). Here, we report the final overall survival (OS; secondary end point) outcomes for the intention-to-treat population.</div></div><div><h3>Methods</h3><div>Between January 2016 and February 2018, 449 eligible patients with an <em>EGFR</em> exon 19del or L858R mutation and no central nervous system metastases were randomized (1:1) to ERL (150 mg/day) with RAM (10 mg/kg every two weeks, N = 224) or placebo (N = 225).</div></div><div><h3>Results</h3><div>At data cutoff, 297 deaths were reported (overall event rate = 66%), with a median follow-up of 45.1 months (interquartile range: 26.7–71.2), an OS HR of 0.98 (95% CI: 0.78–1.24, <em>p</em> = 0.864), and median OS of 51.1 months (RAM + ERL) and 46.0 months (placebo + ERL). Outcomes in subsets of patients with poor prognosis (L858R or <em>TP53</em> co-mutation) suggest a directional improvement in OS (L858R: HR = 0.87, 95% CI: 0.62–1.22; exon 19del: HR = 1.13, 95% CI: 0.83–1.55; <em>TP53</em> co-mutation: HR = 0.83, 95% CI: 0.58–1.19; <em>TP53</em>-wild-type: HR = 1.22, 95% CI: 0.87–1.72). Treatment-emergent T790M rates were similar between arms. Over 80% of patients received post-study discontinuation therapy (&gt;50% received osimertinib in comparable numbers between arms). The safety profile for RAM + ERL was consistent with previous reports with no increased toxicity over time or new safety signals observed.</div></div><div><h3>Conclusion</h3><div>In RELAY, OS was not significantly improved with similar long OS durations in both treatment arms.</div></div><div><h3>Clinical Trial Information</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> Identifier: <span><span>NCT02411448</span><svg><path></path></svg></span></div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 487-499"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer","authors":"Aurélie Swalduz MD, PhD ,&nbsp;Camille Schiffler ,&nbsp;Hubert Curcio MD ,&nbsp;Bana Ambasager ,&nbsp;Gabriel Le Moel MD ,&nbsp;Didier Debieuvre MD ,&nbsp;Jean-Marc Dot MD ,&nbsp;Michael Duruisseaux MD, PhD ,&nbsp;Pierre Fournel MD ,&nbsp;Luc Odier MD ,&nbsp;Sylvie Demolombe MD ,&nbsp;Acya Bizieux-Thaminy MD ,&nbsp;Annie Peytier MD ,&nbsp;Roland Schott MD ,&nbsp;Stéphane Hominal MD ,&nbsp;Claire Tissot MD ,&nbsp;Pierre Bombaron MD ,&nbsp;Séverine Metzger ,&nbsp;Mathilde Donnat ,&nbsp;Sandra Ortiz-Cuaran ,&nbsp;Maurice Pérol MD","doi":"10.1016/j.jtho.2024.12.011","DOIUrl":"10.1016/j.jtho.2024.12.011","url":null,"abstract":"<div><h3>Objectives</h3><div>Genomic profiling is a major component for first-line treatment decisions in patients with NSCLC and the timeliness of biomarker testing is essential to improve time to treatment initiation (TTI) or avoid inappropriate treatment.</div></div><div><h3>Methods</h3><div>The phase III LIquid Biopsy for the Early detection of LUng cancer Lesion trial (NCT03721120) included patients with radiological suspicion of advanced lung cancer. They were randomized (1:1), the control arm receiving diagnostic procedures according to each center’s practice, and the liquid biopsy arm with additional testing performed at the first visit using the InVisionFirst-Lung assay. Treatment initiation and type were defined according to the European Society for Medical Oncology guidelines. Primary endpoint was the time from randomization to initiation of appropriate treatment on the basis of informative genomic and pathological results in the intention-to-treat population.</div></div><div><h3>Results</h3><div>A total of 319 patients were enrolled (liquid biopsy [LB]: 161; control: 158). The median age was 68 years, 28.8% were non-smokers, 18.1% had a performance status of 2 or higher, and 56.7% had adenocarcinoma. In the LB arm, 81% of patients had circulating tumor DNA findings. The mean TTI was not significantly reduced (LB: 29.0 d; control 34 d (<em>p</em> = 0.26)). Sensitivity analyses found a shorter TTI in patients from the LB arm who received systemic treatment (LB: 29.1 d; control: 38.9 d, <em>p</em> = 0.01), in patients with advanced non-squamous NSCLC (LB: 29.5 d; control: 40.3 d, <em>p</em> = 0.01), and in patients with first-line targetable alterations (LB: 21d; control 37.4 d) (<em>p</em> = 0.004). Time to contributory genomic results was significantly reduced (LB: 17.9 d; control: 25.6 d, <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Early liquid biopsy testing did not significantly shorten the TTI in unselected patients referred for suspected advanced lung cancer. Nevertheless, it could reduce the TTI in patients eligible for systemic treatment, particularly for those with actionable alterations.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Pages 437-450"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.26 Investigating for Blood Circulating N-Linked Glycoproteins Associated With Immunotherapy Response in Pleural Mesothelioma","authors":"Pierre Marchal ,&nbsp;Joel Spies ,&nbsp;Sophie Braga Lagache ,&nbsp;Lydie Lane ,&nbsp;Manfred Heller ,&nbsp;Ferdinando Cerciello","doi":"10.1016/j.jtho.2025.03.029","DOIUrl":"10.1016/j.jtho.2025.03.029","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S11"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OA02.01 Selective Translation of PBK (PDZ-Binding Kinase) is a Novel Mechanism of Drug Tolerance to Targeted Therapies in EGFR-Mutant Lung Cancer","authors":"Camille Léonce ,&nbsp;Anne-Laure Desage ,&nbsp;Nour El-Houda Mourksi ,&nbsp;Geneviève De Souza ,&nbsp;Béatrice Vanbervliet ,&nbsp;Camille Charrondière ,&nbsp;Constance Nicq ,&nbsp;Aurélie Swalduz ,&nbsp;Gabriel Ichim ,&nbsp;Jean-Jacques Diaz ,&nbsp;Christine Lovly ,&nbsp;Julien Mazières ,&nbsp;Mayeul Tabutin ,&nbsp;Maurice Pérol ,&nbsp;Sylvie Lantuejoul ,&nbsp;Olivier Calvayrac ,&nbsp;Fabien Forest ,&nbsp;Virginie Marcel ,&nbsp;Pierre Saintigny ,&nbsp;Sandra Ortiz- Cuaran","doi":"10.1016/j.jtho.2025.03.005","DOIUrl":"10.1016/j.jtho.2025.03.005","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S1"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP01.01 Oncogenic Signaling is Rewired to Support Nucleotide Metabolism in Acquired Resistance to Targeted Therapies in NSCLC","authors":"Jaime L. Schneider ,&nbsp;Yutong Dai ,&nbsp;Ishita Dhiman ,&nbsp;Jingpeng Chen ,&nbsp;Shakchhi Joshi ,&nbsp;Kiran Kurmi ,&nbsp;Morgan Payne ,&nbsp;Brandon Gassaway ,&nbsp;Steven Gygi ,&nbsp;Jessica J. Lin ,&nbsp;Aaron Hata ,&nbsp;Marcia Haigis","doi":"10.1016/j.jtho.2025.03.009","DOIUrl":"10.1016/j.jtho.2025.03.009","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 4","pages":"Page S3"},"PeriodicalIF":21.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}